載入...
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma
Mantle cell lymphoma (mcl) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. Patients typically require multiple lines of therapy, and those with relapsed or refractory (r/r) disease have a very poor prognosis. The Bruton tyrosine kinase (btk)...
Na minha lista:
| 發表在: | Curr Oncol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Multimed Inc.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6476444/ https://ncbi.nlm.nih.gov/pubmed/31043832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4345 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|